Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98882 | 0.88 | TDP1 (0.61) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL57166 | 0.87 | TDP1 (1.00) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL29475175 | 0.87 | TDP1 (1.00) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| Methyl Alcohol SCHEMBL28304524 | 0.85 | TDP1 (0.86) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL28093598 | 0.84 | TDP1 (0.95) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL5052440 | 0.83 | HPRT1 (0.65) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL10531193 | 0.81 | TSHR (0.65) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL5255439 | 0.81 | TSHR (0.65) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL28307480 | 0.80 | TDP1 (0.57) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 | |
| SCHEMBL12748810 | 0.80 | TDP1 (0.57) | TDP1SMN1; SMN2TSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110231206-A | The pre-treating method of persistence organic pollutant in a kind of quick measurement Atmospheric particulates | 北京化工大学 | 2019-09-13 | — | — | CN | claimed |
| CN-110231206-A | The pre-treating method of persistence organic pollutant in a kind of quick measurement Atmospheric particulates | 北京化工大学 | 2019-09-13 | — | — | CN | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2714681-B1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9006257-B2 | Bicyclic compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012162365-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-7858636-B2 | Use as coloring in coatings, printing inks and plastics, for producing aqueous polymer dispersions which absorb in the near infrared region, for producing markings which absorb infrared light and are invisible to the human eye, as infrared absorbers for heat management, active components in photovoltaics | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20100203650-A1 | BIOMOLECULE BINDING LIGANDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| US-5138098-A | Catalytic actlation using complexing agent | AMOCO CORPORATION (US) | 1992-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210844-A1 | BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | TDP1 1342/4885SMN1; SMN2 963/4885TSHR 3909/4885 |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | TDP1 3403/4885SMN1; SMN2 600/4885TSHR 4522/4885 |
| US-20100203650-A1 | BIOMOLECULE BINDING LIGANDS | C3AR1, GRB7, C1R | TDP1 4838/4885SMN1; SMN2 4617/4885TSHR 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.